Venkatesan Jay — SEC insider filings
SEC reporting owner CIK 1413350. 28 insider filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 28 filings on record, filed 2020-12-22 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 10 legs across 7 filings — 494,102 shares, $1,148,835 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 718,354 shares, $8,853,664 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 47.
- Largest priced transaction: sale of 400,000 shares @ $9.40 ($3,760,000) in ALPINE IMMUNE SCIENCES, INC., filed 2021-09-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | Director | 17 | 9 legs · 493,513 sh · $1,147,787 | 2 legs · 318,354 sh · $5,093,664 | 30 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) | Director, 10% owner | 6 | — | 1 leg · 400,000 sh · $3,760,000 | 10 |
| Serina Therapeutics, Inc. (SER) | Director | 5 | 1 leg · 589 sh · $1,048 | — | 7 |
Insider filings — Venkatesan Jay
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Serina Therapeutics, Inc. (SER) | Purchase (P): 589 @ $1.78 · Conversion (C): 224,152 @ $2.25 · Grant/award (A): 15,250 (derivative) @ $0 · Conversion (C): 96,525 (derivative) @ $2.25 | EDGAR |
| 2026-04-21 | 4 | Serina Therapeutics, Inc. (SER) | Grant/award (A): 7,553 @ $1.94 | EDGAR |
| 2025-11-10 | 4 | Serina Therapeutics, Inc. (SER) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-04-10 | 4 | Serina Therapeutics, Inc. (SER) | Grant/award (A): 96,525 (derivative) @ $5.18 | EDGAR |
| 2025-02-13 | 4 | Serina Therapeutics, Inc. (SER) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4/A | Elicio Therapeutics, Inc. (ELTX) | Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 | EDGAR |
| 2024-11-29 | 4 | Elicio Therapeutics, Inc. (ELTX) | Option exercise/expiry (X): 50,000 @ $0.01 · Option exercise/expiry (X): 50,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Elicio Therapeutics, Inc. (ELTX) | Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 · Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 · Purchase (P): 50,000 (derivative) @ $0 · Purchase (P): 50,000 (derivative) @ $4.99 · +2 more | EDGAR |
| 2023-12-29 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2022-07-19 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) | Option exercise (M): 20,063 @ $0.45 · Option exercise (M): 20,063 (derivative) @ $0.45 | EDGAR |
| 2022-05-27 | 4/A | Angion Biomedica Corp. (ANGN) | Option exercise/expiry (X): 396,329 @ $6.43 · Sale (S): 159,177 @ $16 · Conversion (C): 262 @ $11.57 · Option exercise/expiry (X): 396,329 (derivative) @ $0 | EDGAR |
| 2022-05-27 | 4 | Angion Biomedica Corp. (ANGN) | Purchase (P): 11,313 @ $1.25 | EDGAR |
| 2022-05-25 | 4 | Angion Biomedica Corp. (ANGN) | Purchase (P): 50,000 @ $1.23 · Purchase (P): 32,200 @ $1.24 | EDGAR |
| 2022-03-04 | 4 | Angion Biomedica Corp. (ANGN) | Grant/award (A): 600,000 (derivative) @ $0 · Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2022-01-04 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-12-29 | 4 | Angion Biomedica Corp. (ANGN) | Purchase (P): 66,907 @ $2.55 · Purchase (P): 210,337 @ $2.66 | EDGAR |
| 2021-12-22 | 4 | Angion Biomedica Corp. (ANGN) | Purchase (P): 3,527 @ $2.54 | EDGAR |
| 2021-12-20 | 4 | Angion Biomedica Corp. (ANGN) | Purchase (P): 27,883 @ $2.55 · Purchase (P): 13,742 @ $2.54 | EDGAR |
| 2021-12-17 | 4 | Angion Biomedica Corp. (ANGN) | Tax withholding (F): 41,091 @ $13.78 · Purchase (P): 77,604 @ $2.41 | EDGAR |
| 2021-09-21 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) | Sale (S): 400,000 @ $9.40 | EDGAR |
| 2021-04-23 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) | Option exercise (M): 7,650 @ $4.09 · Option exercise (M): 7,650 @ $3.62 · Option exercise (M): 7,650 (derivative) @ $0 · Option exercise (M): 7,650 (derivative) @ $0 | EDGAR |
| 2021-02-11 | 4 | Angion Biomedica Corp. (ANGN) | Tax withholding (F): 31,966 @ $16 · Conversion (C): 165,094 · Option exercise/expiry (X): 237,152 @ $6.43 · Sale (S): 159,177 @ $16 · Conversion (C): 262 @ $11.57 · Conversion (C): 1,804 (derivative) @ $0 · +2 more | EDGAR |
| 2021-02-08 | 4 | Angion Biomedica Corp. (ANGN) | Grant/award (A): 178,920 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) | Grant/award (A): 7,650 (derivative) @ $0 | EDGAR |
| 2020-12-22 | 4 | ALPINE IMMUNE SCIENCES, INC. (ALPN) | Other (J): 993,801 @ $0 · Other (J): 181,024 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1413350 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs